PE20110136A1 - Compuestos organicos - Google Patents
Compuestos organicosInfo
- Publication number
- PE20110136A1 PE20110136A1 PE2010001194A PE2010001194A PE20110136A1 PE 20110136 A1 PE20110136 A1 PE 20110136A1 PE 2010001194 A PE2010001194 A PE 2010001194A PE 2010001194 A PE2010001194 A PE 2010001194A PE 20110136 A1 PE20110136 A1 PE 20110136A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- benzyl
- oxo
- imidazolidin
- isonicotinamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE P ES DE PREFERENCIA ISONICOTINAMIDA, QUINOLIN-4-CARBOXAMIDA; Q ES DE PREFERENCIA 2-OXO-IMIDAZOLIDIN, 5-OXO-1H-1,2,4-TRIAZOL-4(5H)-IL; R2 ES 4-FLUORO-BENCIL, 4-TRIFLUOROMETIL-BENCIL, BENZO-[c][1,2,5]-TIADIAZOL-5-IL-METIL; 4-TRIFLUOROMETOXI-BENCIL, 3,4-DIFLUORO-BENCIL, ENTRE OTROS; R1 ES 5-METIL-1,3,4-OXADIAZOL-2-IL-METIL, 4-FLUOROBENCIL, 1,3,4-OXADIAZOL-2-IL, PIRIDIN-2-IL-METIL, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-(3-(4-FLUORO-BENCIL)-2-OXO-IMIDAZOLIDIN-1-IL)-N-((5-METIL-1,3,4-OXADIAZOL-2-IL)-METIL)-ISONICOTINAMIDA; 2-(3-(BENZO-[c][1,2,5]-TIADIAZOL-5-IL-METIL)-2-OXO-IMIDAZOLIDIN-1-IL)-N-BENCIL-ISONICOTINAMIDA; 2-(3-(4-FLUORO-BENCIL)-2-OXO-IMIDAZOLIDIN-1-IL)-N-(PIRIDIN-2-IL-METIL)-QUINOLIN-4-CARBOXAMIDA; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE ESTEAROIL-CoA-DESATURASA (SCD) UTILES EN EL TRATAMIENTO DE DISLIPIDEMIAS Y TRASTORNOS DEL METABOLISMO DE LIPIDOS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7644308P | 2008-06-27 | 2008-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20110136A1 true PE20110136A1 (es) | 2011-03-17 |
Family
ID=41445023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2010001194A PE20110136A1 (es) | 2008-06-27 | 2009-06-25 | Compuestos organicos |
Country Status (25)
Country | Link |
---|---|
US (2) | US9187426B2 (es) |
EP (1) | EP2307379A2 (es) |
JP (1) | JP5529124B2 (es) |
KR (2) | KR20110022089A (es) |
CN (1) | CN102119152B (es) |
AU (1) | AU2009264242A1 (es) |
BR (1) | BRPI0913966A2 (es) |
CA (1) | CA2729327C (es) |
CL (1) | CL2010001526A1 (es) |
CO (1) | CO6341563A2 (es) |
CR (1) | CR11862A (es) |
CU (1) | CU23914B1 (es) |
EA (1) | EA201100049A1 (es) |
EC (1) | ECSP11010787A (es) |
GT (1) | GT201000376A (es) |
HN (1) | HN2010002774A (es) |
IL (1) | IL210118A0 (es) |
MA (1) | MA32508B1 (es) |
MX (1) | MX2010014572A (es) |
NZ (1) | NZ589962A (es) |
PE (1) | PE20110136A1 (es) |
SG (1) | SG192439A1 (es) |
SV (1) | SV2010003777A (es) |
WO (1) | WO2009156484A2 (es) |
ZA (1) | ZA201008951B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008127349A2 (en) | 2006-08-15 | 2008-10-23 | Novartis Ag | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level |
CN101669030B (zh) | 2007-03-08 | 2016-01-13 | 小利兰·斯坦福大学托管委员会 | 线粒体醛脱氢酶2调节剂和其使用方法 |
JP5507474B2 (ja) | 2008-02-20 | 2014-05-28 | ノバルティス アーゲー | ステアロイル−CoAデサチュラーゼのヘテロ環式阻害剤 |
CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
CA2735593C (en) | 2008-09-03 | 2017-08-15 | Repligen Corporation | Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors |
WO2010028175A1 (en) * | 2008-09-08 | 2010-03-11 | The Board Of Trustees Of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase activity and methods of use thereof |
WO2010062308A1 (en) | 2008-10-28 | 2010-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase and methods of use thereof |
AU2009309019B2 (en) * | 2008-10-31 | 2014-11-13 | Merck Sharp & Dohme Llc | P2X3, receptor antagonists for treatment of pain |
AU2010264698C1 (en) | 2009-06-26 | 2013-05-16 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP 17 |
RU2535671C1 (ru) * | 2010-10-18 | 2014-12-20 | Раквалиа Фарма Инк. | Производные ариламидов в качестве блокаторов ttx-s |
US9359300B2 (en) | 2010-12-06 | 2016-06-07 | Confluence Life Sciences, Inc. | Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds |
US20120142709A1 (en) | 2010-12-06 | 2012-06-07 | Selness Shaun R | Substituted pyridinone-pyridinyl compounds |
US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
ES2543050T3 (es) | 2011-02-28 | 2015-08-14 | Array Biopharma, Inc. | Inhibidores de serina/treonina quinasa |
WO2012118782A1 (en) | 2011-02-28 | 2012-09-07 | Repligen Corporation | Histone deacetylase inhibitors |
US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
EA023064B1 (ru) | 2011-04-28 | 2016-04-29 | Новартис Аг | ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ |
US10457659B2 (en) | 2011-04-29 | 2019-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
US9187462B2 (en) | 2011-08-04 | 2015-11-17 | Array Biopharma Inc. | Substituted quinazolines as serine/threonine kinase inhibitors |
JP2015503504A (ja) * | 2011-12-23 | 2015-02-02 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | ヘテロアリールおよびその使用 |
KR102093526B1 (ko) | 2012-03-01 | 2020-03-25 | 어레이 바이오파마 인크. | 세린/트레오닌 키나제 억제제 |
US9181261B2 (en) * | 2012-05-22 | 2015-11-10 | Merck Sharp & Dohme Corp. | TrkA kinase inhibitors, compositions and methods thereof |
WO2014036015A1 (en) | 2012-08-27 | 2014-03-06 | Array Biopharma Inc. | Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
KR20150135332A (ko) | 2013-03-14 | 2015-12-02 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법 |
AU2014228344C1 (en) | 2013-03-15 | 2019-02-07 | Biomarin Pharmaceutical Inc. | HDAC inhibitors |
PT3003039T (pt) | 2013-06-07 | 2021-03-04 | Aclaris Therapeutics Inc | Compostos piridinona-piridinilo substituídos com metil/fluoro-piridinil-metoxilo e compostos piridinona-pirimidinilo substituídos com fluoro-pirimidinil-metoxilo |
MX2016012808A (es) | 2014-04-02 | 2017-01-05 | Intermune Inc | Piridinonas anti-fibroticas. |
PE20170682A1 (es) | 2014-08-04 | 2017-06-15 | Nuevolution As | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncologicas y autoinmunitarias |
WO2017007755A1 (en) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
JP6936796B2 (ja) | 2015-07-06 | 2021-09-22 | ロダン・セラピューティクス,インコーポレーテッド | ヒストンデアセチラーゼのヘテロハロ阻害剤 |
WO2017043341A1 (ja) * | 2015-09-08 | 2017-03-16 | 住友化学株式会社 | トリアゾール化合物 |
WO2017076888A1 (en) * | 2015-11-03 | 2017-05-11 | Janssen Pharmaceutica Nv | 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same |
EA201991650A1 (ru) | 2017-01-06 | 2020-01-20 | Юманити Терапьютикс, Инк. | Способы лечения неврологических расстройств |
US9951069B1 (en) | 2017-01-11 | 2018-04-24 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
KR102577137B1 (ko) * | 2017-06-20 | 2023-09-11 | 라퀄리아 파마 인코포레이티드 | Nav1.7 및 Nav1.8 차단제로 쓰이는 아미드 유도체 |
US11225475B2 (en) | 2017-08-07 | 2022-01-18 | Alkermes, Inc. | Substituted pyridines as inhibitors of histone deacetylase |
EP3700934A4 (en) | 2017-10-24 | 2021-10-27 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THESE COMPOUNDS |
US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
CN114222574A (zh) * | 2019-04-30 | 2022-03-22 | 瓦洛健康股份有限公司 | 抑制usp36 |
EP4076657A1 (en) | 2019-12-20 | 2022-10-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
CN115666566A (zh) | 2020-03-27 | 2023-01-31 | 阿克拉瑞斯治疗股份有限公司 | 用于免疫病况的治疗的mk2途径抑制剂的口服组合物 |
US11613532B2 (en) | 2020-03-31 | 2023-03-28 | Nuevolution A/S | Compounds active towards nuclear receptors |
US11780843B2 (en) | 2020-03-31 | 2023-10-10 | Nuevolution A/S | Compounds active towards nuclear receptors |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6133172A (ja) * | 1984-07-24 | 1986-02-17 | Kotobuki Seiyaku Kk | 1,3−置換−2−イミダゾリジノン誘導体,胃腸運動亢進剤及びその製造方法 |
US4600430A (en) * | 1985-02-22 | 1986-07-15 | Eli Lilly And Company | Pyridinylimidazolidinone compounds |
JPH0249725A (ja) * | 1988-05-13 | 1990-02-20 | Tanabe Seiyaku Co Ltd | 脳代謝賦活剤 |
JP3916092B2 (ja) | 1993-09-17 | 2007-05-16 | 杏林製薬株式会社 | イミダゾリジノン誘導体とその酸付加塩及び老年性痴呆症の治療薬 |
US5607932A (en) | 1994-07-12 | 1997-03-04 | Janssen Pharmaceutica N.V. | Heterocyclic derivatives of azolones |
DE19540027A1 (de) * | 1995-10-27 | 1997-04-30 | Gruenenthal Gmbh | Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe |
CA2367856C (en) | 1999-03-29 | 2013-10-15 | Uutech Limited | Analogs of gastric inhibitory peptide and their use for treatment of diabetes |
CA2379604A1 (en) | 1999-09-28 | 2001-04-05 | Bayer Corporation | Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use |
US6987001B2 (en) | 2000-02-24 | 2006-01-17 | Xenon Pharmaceuticals Inc. | Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents |
JP2003535860A (ja) * | 2000-06-05 | 2003-12-02 | ドン・ア・ファーム・カンパニー・リミテッド | 新規なオキサゾリジノン誘導体及びその製造方法 |
CA2430987A1 (en) | 2000-09-26 | 2002-04-04 | Xenon Genetics, Inc. | Methods and compositions employing a novel stearoyl-coa desaturase-hscd5 |
GB0200283D0 (en) * | 2002-01-08 | 2002-02-20 | Smithkline Beecham Plc | Compounds |
WO2004009558A2 (en) | 2002-07-24 | 2004-01-29 | Ptc Therapeutics, Inc. | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations |
JP2004107323A (ja) * | 2002-07-26 | 2004-04-08 | Nippon Nohyaku Co Ltd | 新規なハロアルキルスルホンアニリド誘導体及び除草剤並びにその使用方法 |
US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
PL374610A1 (en) * | 2002-07-31 | 2005-10-31 | Schering Aktiengesellschaft | Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines |
WO2006034446A2 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridine derivatives for inhibiting human stearoyl-coa-desaturase |
MX2007003325A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa. |
JP2009513563A (ja) * | 2005-06-03 | 2009-04-02 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトのステアロイル−CoAデサチュラーゼ阻害剤としてのアミノチアゾール誘導体 |
-
2009
- 2009-06-25 PE PE2010001194A patent/PE20110136A1/es not_active Application Discontinuation
- 2009-06-25 BR BRPI0913966A patent/BRPI0913966A2/pt not_active IP Right Cessation
- 2009-06-25 KR KR1020117002017A patent/KR20110022089A/ko not_active Application Discontinuation
- 2009-06-25 SG SG2013049614A patent/SG192439A1/en unknown
- 2009-06-25 AU AU2009264242A patent/AU2009264242A1/en not_active Abandoned
- 2009-06-25 MX MX2010014572A patent/MX2010014572A/es not_active Application Discontinuation
- 2009-06-25 JP JP2011515392A patent/JP5529124B2/ja not_active Expired - Fee Related
- 2009-06-25 WO PCT/EP2009/057998 patent/WO2009156484A2/en active Application Filing
- 2009-06-25 EP EP09769332.9A patent/EP2307379A2/en not_active Withdrawn
- 2009-06-25 CN CN200980131152.2A patent/CN102119152B/zh not_active Expired - Fee Related
- 2009-06-25 EA EA201100049A patent/EA201100049A1/ru unknown
- 2009-06-25 CA CA2729327A patent/CA2729327C/en not_active Expired - Fee Related
- 2009-06-25 KR KR1020137017503A patent/KR20130084328A/ko not_active Application Discontinuation
- 2009-06-25 NZ NZ589962A patent/NZ589962A/xx not_active IP Right Cessation
- 2009-06-25 US US13/000,413 patent/US9187426B2/en not_active Expired - Fee Related
-
2010
- 2010-12-13 ZA ZA2010/08951A patent/ZA201008951B/en unknown
- 2010-12-20 IL IL210118A patent/IL210118A0/en unknown
- 2010-12-21 SV SV2010003777A patent/SV2010003777A/es unknown
- 2010-12-21 CR CR11862A patent/CR11862A/es not_active Application Discontinuation
- 2010-12-23 CL CL2010001526A patent/CL2010001526A1/es unknown
- 2010-12-24 HN HN2010002774A patent/HN2010002774A/es unknown
- 2010-12-27 GT GT201000376A patent/GT201000376A/es unknown
- 2010-12-27 CU CU2010000262A patent/CU23914B1/es not_active IP Right Cessation
-
2011
- 2011-01-26 MA MA33563A patent/MA32508B1/fr unknown
- 2011-01-27 CO CO11009246A patent/CO6341563A2/es active IP Right Grant
- 2011-01-27 EC EC2011010787A patent/ECSP11010787A/es unknown
-
2015
- 2015-10-09 US US14/879,583 patent/US20160289191A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN102119152A (zh) | 2011-07-06 |
US9187426B2 (en) | 2015-11-17 |
HN2010002774A (es) | 2013-01-28 |
ZA201008951B (en) | 2012-02-29 |
CU20100262A7 (es) | 2011-11-15 |
US20110105530A1 (en) | 2011-05-05 |
JP2011525896A (ja) | 2011-09-29 |
WO2009156484A3 (en) | 2010-05-14 |
EP2307379A2 (en) | 2011-04-13 |
MX2010014572A (es) | 2011-03-24 |
CU23914B1 (es) | 2013-07-31 |
JP5529124B2 (ja) | 2014-06-25 |
CO6341563A2 (es) | 2011-11-21 |
EA201100049A1 (ru) | 2011-08-30 |
MA32508B1 (fr) | 2011-07-03 |
ECSP11010787A (es) | 2011-02-28 |
CN102119152B (zh) | 2014-07-02 |
WO2009156484A2 (en) | 2009-12-30 |
AU2009264242A1 (en) | 2009-12-30 |
BRPI0913966A2 (pt) | 2015-11-17 |
US20160289191A1 (en) | 2016-10-06 |
CA2729327A1 (en) | 2009-12-30 |
KR20130084328A (ko) | 2013-07-24 |
CL2010001526A1 (es) | 2011-07-01 |
GT201000376A (es) | 2013-09-09 |
KR20110022089A (ko) | 2011-03-04 |
SV2010003777A (es) | 2011-07-05 |
SG192439A1 (en) | 2013-08-30 |
NZ589962A (en) | 2012-12-21 |
IL210118A0 (en) | 2011-02-28 |
CA2729327C (en) | 2016-10-11 |
CR11862A (es) | 2011-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20110136A1 (es) | Compuestos organicos | |
PE20120620A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
PE20141375A1 (es) | Activadores de glucoquinasa | |
PE20091828A1 (es) | Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino como inhibidores de edg-2 | |
PE20121732A1 (es) | Derivados de ciclohexano espiro-condensado como inhibidores de hsl utiles en el tratamiento de la diabetes | |
PE20191757A1 (es) | Compuestos heterociclicos utiles como inhibidores dobles de atx/ca | |
PE20141120A1 (es) | Compuestos heterociclicos | |
PE20141682A1 (es) | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio | |
PE20141361A1 (es) | Compuesto heterociclico dihidroxi aromatico | |
PE20060937A1 (es) | Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2) | |
PE20090649A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
PE20081545A1 (es) | Derivados de sulfonamida como inhibidores de acido graso sintasas | |
PE20140934A1 (es) | Derivados de pirazol | |
PE20060079A1 (es) | DERIVADOS DE PIRIDILO COMO ANTAGONISTAS DEL RECEPTOR mGlus5 | |
PE20130405A1 (es) | Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso | |
PE20110843A1 (es) | Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica | |
NO20083514L (no) | Heterobicykliske sulfonamidderivater for behandling av diabetes | |
PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
PE20070136A1 (es) | COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1 | |
PE20091724A1 (es) | Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7 | |
PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
PE20150636A1 (es) | Dicianopiridinas alquilamino-sustituidas y sus profarmacos de ester de aminoacido | |
PE20091486A1 (es) | Derivado de pirrolopirimidina como inhibidor de la enzima pi3k | |
PE20080319A1 (es) | Dihidrotienopirimidinas como agentes inhibidores de pde-4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |